ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP81-24 Health Equity Certification 2025 Launch
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 3301 - 3310 လၢ 4229 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP78-24 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2024
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP84-24 Commercial Pharmacy Benefit Exclusion for Tremfya® and Ocrevus Zunovo™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP83-24 MHCP Pharmacy Benefit Exclusion for Tremfya®, Tecentriq Hybreza™ and Ocrevus Zunovo™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP82-24 Enhanced Authorization Submissions through Availity Essentials
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP80-24 Commercial Pharmacy Benefit Exclusion for Select Medications
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 13, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-mhcp-pharmprogpolicynotifctn-effective-12-1-24.pdf
တၢ်ဃုပှ့ၤတၢ် ဒီးတၢ်မၤလိ
2025 Spanish Individual & Family Decision Guide
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2024 November Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P72-24 Prime Therapeutics Management (UM) Program: Medical Drug Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 01, 2024